487 related articles for article (PubMed ID: 26230396)
1. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
[TBL] [Abstract][Full Text] [Related]
2. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
[TBL] [Abstract][Full Text] [Related]
5. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
7. Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.
Drozd K; Ahmadi A; Deng Y; Jiang B; Petryk J; Thorn S; Stewart D; Beanlands R; deKemp RA; DaSilva JN; Mielniczuk LM
J Nucl Cardiol; 2017 Dec; 24(6):1979-1989. PubMed ID: 27688036
[TBL] [Abstract][Full Text] [Related]
8. The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan).
Tan XY; He JG
Pathol Res Pract; 2009; 205(7):473-82. PubMed ID: 19232841
[TBL] [Abstract][Full Text] [Related]
9. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
[TBL] [Abstract][Full Text] [Related]
10. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography.
Inagaki T; Pearson JT; Tsuchimochi H; Schwenke DO; Saito S; Higuchi T; Masaki T; Umetani K; Shirai M; Nakaoka Y
Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1021-H1036. PubMed ID: 33481696
[TBL] [Abstract][Full Text] [Related]
13. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Angus JA; Soeding PF; Hughes RJA; Wright CE
Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
[TBL] [Abstract][Full Text] [Related]
14. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F
Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952
[TBL] [Abstract][Full Text] [Related]
15. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.
Schroll S; Arzt M; Sebah D; Stoelcker B; Luchner A; Budweiser S; Blumberg FC; Pfeifer M
Scand J Clin Lab Invest; 2008; 68(4):270-6. PubMed ID: 18612919
[TBL] [Abstract][Full Text] [Related]
17. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
Surie S; Reesink HJ; Marcus JT; van der Plas MN; Kloek JJ; Vonk-Noordegraaf A; Bresser P
Clin Cardiol; 2013 Nov; 36(11):698-703. PubMed ID: 24037998
[TBL] [Abstract][Full Text] [Related]
18. Dual Endothelin Receptor Blockade Abrogates Right Ventricular Remodeling and Biventricular Fibrosis in Isolated Elevated Right Ventricular Afterload.
Nielsen EA; Sun M; Honjo O; Hjortdal VE; Redington AN; Friedberg MK
PLoS One; 2016; 11(1):e0146767. PubMed ID: 26765263
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor mediates pulmonary hypertension and right ventricular remodeling induced by inhaled nicotine.
Fried ND; Morris TM; Whitehead A; Lazartigues E; Yue X; Gardner JD
Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1526-H1534. PubMed ID: 33577434
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
Kosanovic D; Kojonazarov B; Luitel H; Dahal BK; Sydykov A; Cornitescu T; Janssen W; Brandes RP; Davie N; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Schermuly RT
Respir Res; 2011 Jun; 12(1):87. PubMed ID: 21699729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
